List of Dyanavel Xr drug patents

Dyanavel Xr is owned by Tris Pharma Inc.

Dyanavel Xr contains Amphetamine; Amphetamine Aspartate/Dextroamphetamine Sulfate.

Dyanavel Xr has a total of 6 drug patents out of which 0 drug patents have expired.

Dyanavel Xr was authorised for market use on 19 October, 2015.

Dyanavel Xr is available in suspension, extended release;oral dosage forms.

The generics of Dyanavel Xr are possible to be released after 29 March, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675703 TRIS PHARMA INC Modified release formulations containing drug - ion exchange resin complexes
Mar, 2027

(4 years from now)

US8747902 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

US8597684 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

US8883217 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

US10086087 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(4 years from now)

US8062667 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2029

(6 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 19 October, 2015

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in